Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,528.29
(
-0.80%
)
US TECH 100
23,394.40
(
-0.53%
)
Dow Jones
45,778.04
(
-0.93%
)
Brent Oil
100.46
(
3.79%
)
Bitcoin
70,324.00
(
-0.81%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 69
Posts 4516
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: AlpineBV_Miller post# 102812

Saturday, 08/28/2010 11:52:55 PM

Saturday, August 28, 2010 11:52:55 PM

Post# of 257275

Ixebepilone, which sees very little use in 3rd line BCa from what I'm told, is likely the reason why this got hung up.



I looked at T-DM1 3rd line result more closely today. I don't see patients in this trial used gemcitabine before. So, at least two approved MBC treatments not used in study population.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today